Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.82 USD | +1.98% | +1.50% | -23.75% |
Financials (USD)
Sales 2024 * | 529M | Sales 2025 * | 681M | Capitalization | 3.2B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | 121M | EV / Sales 2024 * | 6.3 x |
Net Debt 2024 * | 139M | Net Debt 2025 * | 24.31M | EV / Sales 2025 * | 4.73 x |
P/E ratio 2024 * |
-3,173
x | P/E ratio 2025 * |
27.7
x | Employees | 517 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.75% |
Latest transcript on Amicus Therapeutics, Inc.
1 day | +1.98% | ||
1 week | +1.50% | ||
Current month | -8.15% | ||
1 month | -6.16% | ||
3 months | -12.95% | ||
6 months | -0.73% | ||
Current year | -23.75% |
Managers | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Simon Harford
DFI | Director of Finance/CFO | 64 | 23-08-20 |
Pat O’Sullivan
COO | Chief Operating Officer | - | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Lynn Bleil
BRD | Director/Board Member | 60 | 18-09-10 |
Burke W. Whitman
BRD | Director/Board Member | 68 | 19-06-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.91% | 16 M€ | -7.93% | ||
0.32% | 0 M€ | 0.00% | - | |
0.29% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 10.82 | +1.98% | 4,620,529 |
24-04-19 | 10.61 | +2.71% | 2,888,014 |
24-04-18 | 10.33 | -2.09% | 1,725,749 |
24-04-17 | 10.55 | -0.09% | 3,013,059 |
24-04-16 | 10.56 | -0.94% | 2,800,442 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.75% | 3.2B | |
-0.02% | 42.11B | |
+45.38% | 40.08B | |
+5.04% | 40B | |
-11.32% | 26.87B | |
+5.25% | 24.58B | |
-23.83% | 18.44B | |
-1.62% | 11.94B | |
+22.75% | 11.66B | |
+6.44% | 11.01B |
- Stock Market
- Equities
- FOLD Stock